Legend Capital and Lyfe Capital led a CNY1.5b (approximately USD226.6m) Series B for China-based biotech firm RecBio, with participation from Sequoia Capital and Temasek’s Vertex Ventures. Other investors include China’s HT Capital, Co-Stone Asset Management, Yuanbio Venture Capital, Qingsong Capital, and China Everbright Limited. Read more